Overview
Areas of Research/Interest
- Optimizing biomarker directed treatment for late-stage lung cancer
- Optimizing treatment for patients with lung cancer and brain metastases
- Finding novel targets in early and advanced stage lung cancer
- Optimizing access to health care in women and minorities facing lung cancer
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Journal Article Lung Cancer · January 2026 BACKGROUND: Tarlatamab, a bispecific T-cell engager, is the first treatment in many years to significantly improve overall survival in relapsed extensive stage small cell lung cancer (ES-SCLC). However, implementation of this therapy has been challenging d ... Full text Link to item CiteGiven TKIs With High CNS Penetrance, Systemic Therapy Should Be Administered Before Radiation Therapy for CNS Metastases.
Journal Article J Thorac Oncol · December 2025 Full text Link to item CiteMulti-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.
Journal Article JCO Precis Oncol · October 2025 Full text Link to item CiteRecent Grants
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Henlius USA Inc. · 2025 - 2030A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations
Clinical TrialPrincipal Investigator · Awarded by Iambic Therapeutics, Inc. · 2025 - 2030Phanes Therapeutics / The SKYBRIDGE study, an Open-label, Multicenter, Dose Escalation and Dose Expansion Phase 1/2 Study with PT217 Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas Th
Clinical TrialPrincipal Investigator · Awarded by Phanes Therapeutics, Inc. · 2025 - 2030View All Grants
Education, Training & Certifications
University of Queensland (Australia) ·
2017
M.D.